Testimonials
John J. O’Leary MD, PhD, MSc, MA, FRCPath, FFPathRCPI, FTCD. Said:
“The Vaccinogen autologous cancer cell vaccination approach is fully compliant with this scientific
thinking. Using the patient’s own tumour cells to fight their cancer, with the full orchestra of genomic
and proteome changes, complexed to an immunological adjuvant, offers the best approach currently
available in cancer tumour immunology and therapeutics. Refining the neo-proteins and neo-peptides
of cancer cells as signatures for vaccine generation is smart medicine and essentially offers a
paradigm shift in how we approach cancer therapeutics.
Vaccinogen’s results in colon cancer are truly remarkable and now I believe they need to be given the
opportunity to extend their approaches to other cancers and other cancer disease contexts, to
produce the ultimate in cancer vaccination and deliver ‘tomorrow’s medicine today.”
Yours sincerely,
John J. O’Leary MD, PhD, MSc, MA, FRCPath, FFPathRCPI, FTCD.
Chair of Pathology, Trinity College Dublin, Ireland.
Director of Pathology, The Coombe Women and Infants University Hospital, Dublin.
Consultant Histopathologist St. James’s Hospital, Dublin.
Benjamin S. Carson Sr. MD Said:
“A personalized disease like cancer requires a personalized weapon.
I believe that Vaccinogen has developed the first truly personalized – and potentially commercializable – approach to combat cancer and that is why I joined Vaccinogen’s Board as Chairman in 2014 and remained on the Board until I formally announced my candidacy for President of the United States.
I spent my career as a physician pushing boundaries to achieve my dreams of saving and improving the lives of my patients who previously had no options. As a company, Vaccinogen is working towards a similar goal. The company’s co-founder, Dr. Mike Hanna, understood early on that cancer is a heterogeneous disease and has worked diligently over the past 50 years to prove his thesis – and developed a solution. His solution, OncoVax®, demonstrated in an intitial Phase III trial, a reduced risk of colon cancer occurance by 61% after surgery to remove Stage 2 tumors when compared to surgery alone. If results of the upcoming confirmatory Phase IIIb study and other similar studies are similar, I believe that OncoVax® will change how we think about treating cancer across the board. In addition to OncoVax®, I am excited at the approach Vaccinogen is taking to develope Oncavert, a potential vaccine to prevent the inital development of cancer.”
Sincerely,
Benjamin S. Carson Sr. MD
Emeritus Professor of Neurosurgery, Oncology,
Plastic Surgery and Pediatrics
John Hopkins Medicine
President and CEO
American Business Collaborative, LLC
US Presidential Candidate